Growth differentiation factor 15 - a new molecular target in inflammatory bowel disease: Progress and challenges

The study by Ruiz-Malagón et al marks a significant advancement in understanding the role of growth differentiation factor 15 (GDF15) in inflammatory bowel disease (IBD). Using both in vivo and in vitro models, the researchers detected elevated circulating GDF15 levels in patients with both ulcerative colitis (UC) and Crohn's disease (CD), and its level correlates with markers of inflammation and intestinal permeability. Utilizing colonic organoids and T84 cells, they demonstrated that GDF15 increases intestinal permeability by reducing the expression of zonula occludens-1 (ZO-1) and claudin 1. They concluded that targeting GDF15 may offer a promising strategy to preserve intestinal barrier integrity and potentially reducing immune overactivation. However, results from a small-sample sized study (CD patients 21, UC patients 18, and healthy controls 23) signals interpretation with caution. Genetic approaches are needed to validate the findings that GDF15 alters the intestinal barrier and increases permeability by decreasing the levels of ZO-1 and claudin 1. GDF15 serves as a double-edged mediator with context-dependent protective or pathogenic roles, and clarifying this duality is a critical goal for translational research. Overall, the study represents a critical step in understanding the pathogenesis of IBD, highlighting both progresses made and the work still required for clinical translation.